0.00Open0.00Pre Close0 Volume0 Open Interest9.50Strike Price0.00Turnover346.36%IV-15.86%PremiumJul 26, 2024Expiry Date1.79Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8107Delta0.1073Gamma5.44Leverage Ratio-0.2341Theta0.0003Rho4.41Eff Leverage0.0020Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet